Brennan B M, Rahim A, Adams J A, Eden O B, Shalet S M
Department of Paediatric Oncology, Royal Manchester Children's Hospital, Manchester, UK.
Br J Cancer. 1999 Apr;79(11-12):1859-63. doi: 10.1038/sj.bjc.6690296.
Bone mineral density (BMD), serum osteocalcin and type I collagen C-telopeptide (ICTP) were assessed in a cohort of 31 (16 males) adults who had received cranial irradiation in childhood as part of their treatment for acute lymphoblastic leukaemia (ALL). Markers of bone turnover were compared with those of 35 age and body mass index (BMI) matched young adults (18 male). Growth hormone status had previously been determined using an insulin tolerance test and arginine stimulation test. Eight patients were classified as severe growth hormone deficiency (group 1), 12 patients as growth hormone insufficient (group 2) and 11 patients as normal (group 3). Vertebral trabecular BMD, lumbar spine and femoral neck integral BMD and forearm cortical bone mineral content (BMC) was measured 17.8 (6.8-28.6) years after cranial irradiation and was expressed as Z (standard deviation) scores. There was a significant reduction in vertebral trabecular BMD (median Z score -1.25, P < 0.001), in lumbar spine integral BMD (median Z score -0.74, P = 0.001), in forearm cortical BMC (median Z score -1.35, P < 0.001), and less so in femoral neck integral BMD (median Z score -0.43, P = 0.03). There was no difference among the growth hormone status groups for the following BMD measurements: vertebral trabecular BMD, lumbar spine integral BMD or femoral neck integral BMD (P = 0.8, P = 0.96 and P = 0.4 respectively). There was only a marginal significant difference for BMD at the wrist between growth hormone status groups (P = 0.04). There was no correlation between the BMD measurements with time since or age at diagnosis and no difference in markers of bone turnover between patients and controls; median serum osteocalcin 13.3 and 12.0 ng ml (P = 0.7), respectively, and for ICTP 5.0 and 4.9 microg L (P = 0.67) respectively. In conclusion, there is a highly significant reduction in BMD in young adults following treatment for ALL in childhood. The reduction in BMD affects both trabecular and cortical bone but did not seem to be related to time since diagnosis, age at diagnosis, or current growth hormone status. Possible explanations include a direct effect of chemotherapy, steroids or both on bone during childhood and hence an effect on the accretion of bone mass. In view of the risk of fractures in patients with osteopenia, adults treated for ALL in childhood may be at an increased risk of bone fractures later in life irrespective of the underlying cause of the osteopenia and thus intervention should be considered.
对31名(16名男性)成年患者进行了骨矿物质密度(BMD)、血清骨钙素和I型胶原C末端肽(ICTP)评估,这些患者童年时因急性淋巴细胞白血病(ALL)接受过颅脑照射。将骨转换标志物与35名年龄和体重指数(BMI)匹配的年轻成年人(18名男性)的标志物进行比较。此前已通过胰岛素耐量试验和精氨酸刺激试验确定生长激素状态。8名患者被归类为严重生长激素缺乏(第1组),12名患者为生长激素不足(第2组),11名患者为正常(第3组)。在颅脑照射后17.8(6.8 - 28.6)年测量了椎体小梁BMD、腰椎和股骨颈整体BMD以及前臂皮质骨矿物质含量(BMC),并表示为Z(标准差)评分。椎体小梁BMD显著降低(中位数Z评分 -1.25,P < 0.001),腰椎整体BMD(中位数Z评分 -0.74,P = 0.001),前臂皮质BMC(中位数Z评分 -1.35,P < 0.001),股骨颈整体BMD降低程度较小(中位数Z评分 -0.43,P = 0.03)。在以下BMD测量中,生长激素状态组之间无差异:椎体小梁BMD、腰椎整体BMD或股骨颈整体BMD(分别为P = 0.8、P = 0.96和P = 0.4)。生长激素状态组之间仅腕部BMD存在边缘显著差异(P = 0.04)。BMD测量值与诊断后的时间或诊断时的年龄之间无相关性,患者与对照组之间的骨转换标志物无差异;血清骨钙素中位数分别为13.3和12.0 ng/ml(P = 0.7),ICTP分别为5.0和4.9 μg/L(P = 0.67)。总之,童年ALL治疗后的年轻成年人BMD显著降低。BMD降低影响小梁骨和皮质骨,但似乎与诊断后的时间、诊断时的年龄或当前生长激素状态无关。可能的解释包括化疗、类固醇或两者在童年期对骨骼的直接作用,从而对骨量的积累产生影响。鉴于骨质减少患者骨折的风险,童年时接受ALL治疗的成年人晚年发生骨折的风险可能增加,无论骨质减少的潜在原因如何,因此应考虑进行干预。